Bayer Begins Phase II Study of Soluble Guanylate Cyclase Activator, BAY3283142

Bayer Begins Phase II Study of Soluble Guanylate Cyclase Activator, BAY3283142

By, Admin 23 August 2024

Bayer begins phase II study of soluble guanylate cyclase activator, BAY3283142 in patients with chronic kidney disease

Overview

Bayer announced the start of the ALPINE-1 study, a phase II clinical trial with BAY3283142, an investigational soluble guanylate cyclase (sGC) activator, in patients with chronic kidney disease (CKD). The results of this study have the potential to provide evidence of the sGC activator as a viable treatment option for cardiovascular diseases.

About CKD

  • CKD is a progressive condition that affects more than 10% of the global population, totalling approximately 850 million individuals. 
  • It is a common and potentially deadly condition that is widely underrecognized. It progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. 
  • CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease.

From Bayer’s Pharmaceuticals Division

  • This study marks a significant step forward in our commitment to addressing the high unmet medical need in this patient population and advancing our innovative approach to treat renal disease,” said Dr. Christian Rommel, head of research and development at Bayer’s Pharmaceuticals Division. 
  • In addition, this further strengthens our overall development portfolio. We are dedicated to advancing the development of BAY3283142 to improve outcomes for patients with chronic kidney disease and related cardiovascular conditions.

Statement from the Co-Chair of the ALPINE-1 Study.

  • The change in demography tells us that we are living longer in the future, and people want to spend this time in good health, with healthy kidneys,” said Prof. Christoph Wanner, Senior Professor of Medicine in the Department of Clinical Studies and Epidemiology, University Hospital of Würzburg and Co-Chair of the ALPINE-1 study. 
  • The prevalence of chronic kidney disease (CKD) as one of the top 10 leading causes of mortality underscores the pressing need for effective treatment options. The evaluation of the sGC activator in patients with CKD holds promise in addressing a critical unmet medical need in patient care.

About Phase II ALPINE-1 Study

  • Following the successful first-in-human trials, the goal of the randomized, double-blind, placebo-controlled, multi-center phase II ALPINE-1 study is to assess the efficacy and safety of BAY3283142 in patients with chronic kidney disease. 
  • BAY3283142 is a soluble guanylate cyclase (sGC) activator that represents an innovative approach to modulating the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway with a broad treatment potential in cardiovascular diseases.

About Bayer

  • Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. 
  • The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. 
  • Together, this reflects the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated.

Bayer’s Mission

  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. 
  • In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!